Avacta Group Plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AVCTF research report →
About the company
Avacta Group Plc, a biopharmaceutical enterprise operating at the clinical stage, was established in 2003 and is headquartered in Wetherby, UK. The company specializes in the creation of cancer treatments and diagnostic solutions, leveraging its distinctive Affimer and pre|CISION proprietary platforms. Its operations span the United Kingdom, North America, South Korea, and broader regions of Asia and Europe, structured into two main divisions: Diagnostics and Therapeutics.
- CEO
- Christina Marie Coughlin
- IPO
- 2020
- Employees
- 154
- HQ
- Wetherby, GB
Price Chart
- Market Cap
- $468.40M
- P/E
- -8.31
- P/S
- 3025.97
- P/B
- 128.74
- EV/EBITDA
- -11.88
- Div Yield
- 0.00%
- Gross Margin
- -1031.86%
- Op Margin
- -26756.64%
- Net Margin
- -33961.06%
- ROE
- -2929.47%
- ROIC
- -171.00%
- Revenue
- $112.98K · -0.02%
- Net Income
- $-38,369,781 · 27.39%
- EPS
- $-0.10 · 39.69%
- Op Income
- $-30,230,100
- FCF YoY
- -3.61%
- 52W High
- $1.23
- 52W Low
- $0.40
- 50D MA
- $1.02
- 200D MA
- $0.94
- Beta
- -0.07
- Avg Volume
- 10.25K
Get TickerSpark's AI analysis on AVCTF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our AVCTF coverage
Recent articles, reports, and earnings notes.
No research on AVCTF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AVCTF report →Similar companies
Peers in the same neighborhood.